Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy

Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy

Abstract Focal epilepsy represents one of the most common chronic CNS diseases. The high incidence of drug resistance, devastating comorbidities, and insufficient responsiveness to surgery pose unmet medical challenges. In the quest of novel, disease‐modifying treatment strategies of neuropeptides r...

Full description

Bibliographic Details
Main Authors: Alexandra S Agostinho, Mario Mietzsch, Luca Zangrandi, Iwona Kmiec, Anna Mutti, Larissa Kraus, Pawel Fidzinski, Ulf C Schneider, Martin Holtkamp, Regine Heilbronn, Christoph Schwarzer
Format: Article
Language:English
Published: Springer Nature 2019-09-01
Series:EMBO Molecular Medicine
Subjects:
adeno‐associated virus
learning
memory
neuropeptide
seizure
Online Access:https://doi.org/10.15252/emmm.201809963

Internet

https://doi.org/10.15252/emmm.201809963

Similar Items